DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zometa (Zoledronic Acid) - Published Studies

 
 



Zometa Related Published Studies

Well-designed clinical trials related to Zometa (Zoledronic Acid)

Fracture risk and zoledronic acid therapy in men with osteoporosis. [2012]

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. [2012]

Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. [2012]

Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. [2012]

Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture. [2011.11]

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. [2011.10.29]

Breast-cancer adjuvant therapy with zoledronic acid. [2011.10.13]

Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. [2011.09]

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. [2011.08]

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. [2011.07]

The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. [2011.07]

Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. [2011.07]

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. [2011.06]

Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. [2011.06]

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. [2011.05]

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. [2011.05]

Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. [2011.04]

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011.03.20]

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. [2011.03.05]

Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom. [2011.03]

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. [2011.03]

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. [2011.03]

Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). [2011.01]

Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). [2011.01]

Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. [2011.01]

Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. [2011]

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011]

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. [2010.12.11]

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. [2010.12.10]

Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. [2010.12.01]

Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. [2010.12]

Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. [2010.11]

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. [2010.11]

Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. [2010.10]

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. [2010.10]

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis. [2010.09.02]

Characterization of and risk factors for the acute-phase response after zoledronic acid. [2010.09]

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. [2010.08]

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. [2010.07]

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. [2010.06.15]

Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. [2010.06]

Long term zoledronic acid during androgen blockade for prostate cancer. [2010.06]

Zoledronic Acid Treatment of Osteoporosis: Effects in Men. [2010.05.24]

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. [2010.05]

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. [2010.03.30]

Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. [2010.03]

A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. [2010.03]

Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. [2010.03]

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. [2010.02]

Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. [2010.02]

Potential mediators of the mortality reduction with zoledronic acid after hip fracture. [2010.01]

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. [2010]

Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies. [2010]

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. [2009.11]

Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. [2009.11]

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. [2009.10.03]

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. [2009.10]

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. [2009.08.01]

Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. [2009.07]

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. [2009.05]

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. [2009.05]

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. [2009.04.11]

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. [2009.03.13]

Endocrine therapy plus zoledronic acid in premenopausal breast cancer. [2009.02.12]

The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. [2009.02]

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. [2008.10.01]

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. [2008.09]

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. [2008.09]

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. [2008.06.03]

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. [2008.05]

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. [2008.03.31]

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. [2008.01]

Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. [2008.01]

Zoledronic acid and clinical fractures and mortality after hip fracture. [2007.11.01]

Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. [2007.11]

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. [2007.09.26]

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. [2007.09]

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. [2007.07]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. [2007.05.03]

Treatment with Zoledronic Acid Ameliorates Negative Geometric Changes in the Proximal Femur following Acute Spinal Cord Injury. [2007.05]

Treatment with Zoledronic Acid Ameliorates Negative Geometric Changes in the Proximal Femur following Acute Spinal Cord Injury. [2007.04.07]

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. [2007.03.20]

Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. [2007.03.01]

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. [2007.03.01]

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. [2007.03]

Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. [2007.01]

Dose Dense (CEOP-14) vs Dose Dense and Rituximab (CEOP-14 +R) in High-Risk Diffuse Large Cell Lymphoma. [2007]

Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. [2007]

A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. [2006.09]

Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. [2006.09]

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. [2006.09]

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. [2006.08.01]

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. [2006.05]

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. [2006.02.21]

A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. [2006.01]

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. [2005.09.01]

Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. [2005.06]

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. [2005.05.23]

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. [2005.05.20]

Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. [2005]

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. [2004.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012